Veradermics (MANE) Preferred Stock Liabilities (2024 - 2025)
Veradermics (MANE) posted Preferred Stock Liabilities of $78.9 million for Q4 2025, up 114.06% on a QoQ basis from $36.9 million in Q4 2024, and up 114.06% year-over-year from $36.9 million in Q4 2024.
Veradermics (MANE) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Veradermics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $78.9 million for Q4 2025.
- Quarterly Preferred Stock Liabilities rose 114.06% year-over-year to $78.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $78.9 million (up 114.06% YoY) and the FY2025 annual result came in at $78.9 million, up 114.06% from the prior year.
- Preferred Stock Liabilities was $78.9 million for Q4 2025 at Veradermics, up from $36.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $78.9 million in Q4 2025 and bottomed at $36.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Veradermics | 2.63 Bn | 2.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 78.90 Mn |
| Dec 31, 2024 | 36.86 Mn |